Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment  

作　　者：Arata Nishimoto 

机构地区：[1]Division of Basic Pharmaceutical Science,Department of Pharmacy,Faculty of Pharmaceutical Sciences,Sanyo-Onoda City University,Sanyo-Onoda City 756-0884,Yamaguchi,Japan

出　　处：《World Journal of Gastroenterology》2022年第28期3637-3643,共7页世界胃肠病学杂志（英文版）

摘　　要：Pancreatic cancer is highly aggressive and lethal.Due to the lack of effective methods for detecting the disease at an early stage,pancreatic cancer is frequently diagnosed late.Gemcitabine has been the standard chemotherapy drug for patients with pancreatic cancer for over 20 years,but its anti-tumor effect is limited.Therefore,FOLFIRINOX(leucovorin,fluorouracil,irinotecan,oxaliplatin)as well as combination therapies using gemcitabine and conventional agents,such as cisplatin and capecitabine,has also been administered;however,these have not resulted in complete remission.Therefore,there is a need to develop novel and effective therapies for pancreatic cancer.Recently,some studies have reported that combinations of gemcitabine and targeted drugs have had significant antitumor effects on pancreatic cancer cells.As gemcitabine induced DNA damage response,the proteins related to DNA damage response can be suitable additional targets for novel gemcitabine-based combination therapy.Furthermore,KRAS/RAF/MEK/ERK signaling triggered by oncogenic mutated KRAS and autophagy are frequently activated in pancreatic cancer.Therefore,these characteristics of pancreatic cancer are potential targets for developing effective novel therapies.In this minireview,combinations of gemcitabine and targeted drugs to these characteristics,combinations of targeted drugs,combinations of natural products and anti-cancer agents,including gemcitabine,and combinations among natural products are discussed.

关 键 词：Pancreatic cancer GEMCITABINE Targeted drug Combination therapy 

分 类 号：R735.9[医药卫生—肿瘤]